ReviewJournal of personalized medicine2024
Bridging the Divide: A Review on the Implementation of Personalized Cancer Medicine.
Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Tumor-on-chip as a personalized platform for rapid drug testing in breast cancer.Cell reports. Medicine · 2026Article
- The molecular ICU: a primer on omics, informatics and the future of precision critical care.Critical care (London, England) · 2026Review
- Navigating AI and machine learning in cancer research: an end-to-end translational framework.Journal of translational medicine · 2026Review
- Precision cancer medicine in Europe: a mixed-methods study on infrastructure for extended molecular diagnostics.Journal of cancer research and clinical oncology · 2026Article
- Updated evidence on the accuracy ofQuantitative imaging in medicine and surgery · 2026Review
- Personalized medicine and health equity: overcoming cost barriers and ethical challenges.International journal for equity in health · 2025Review
- Chitosan-Based Drug Delivery Systems for Targeted Chemotherapy in Colorectal Cancer: A Scoping Review.Marine drugs · 2025Article
- Wearable nanopatch platforms for real-time miRNA sensing and editing: a vision for next-generation cancer management.Medical oncology (Northwood, London, England) · 2025Review
- Src and Abl as Therapeutic Targets in Lung Cancer: Opportunities for Drug Repurposing.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Radical resections of hepatopancreatobiliary cancers: balancing surgical innovation, evidence, and societal impact.ANZ journal of surgery · 2025Article
- Deep learning-driven drug response prediction and mechanistic insights in cancer genomics.Scientific reports · 2025Article
- The Design of a Multistage Monitoring Protocol for Dendritic Cell-Derived Exosome (DEX) Immunotherapy: A Conceptual Framework for Molecular Quality Control and Immune Profiling.International journal of molecular sciences · 2025Article
- Multiple Strategies for the Application of Medicinal Plant-Derived Bioactive Compounds in Controlling Microbial Biofilm and Virulence Properties.Antibiotics (Basel, Switzerland) · 2025Review
- Implementing Personalized Cancer Medicine: Insights from a Qualitative Interview Study.Journal of personalized medicine · 2025Article
- Celebrating World Cancer Day: Innovative Biological Approaches to Cancer and their Alignment with Sustainable Development Goals (SDGs).Biological procedures online · 2025Article
- Role of nursing and midwifery in mainstreaming genomics in Australia: mixed-methods study exploring scope of practice and strategies for implementation.Frontiers in genetics · 2025Article
- Computationally reconstructing the evolution of cancer progression risk.bioRxiv : the preprint server for biology · 2024Article
- Nanomedicine mediated thyroid cancer diagnosis and treatment: an approach from generalized to personalized medicine.Discover oncology · 2024Review
- Diagnostics and Therapy for Malignant Tumors.Biomedicines · 2024Review
- From complexity to clarity: A perspective on personalized spine care through genetic, psychosocial, and technological advancements.Journal of craniovertebral junction & spineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The shift towards personalized cancer medicine (PCM) represents a significant transformation in cancer care, emphasizing tailored treatments based on the genetic understanding of cancer at the cellular level. This review draws on recent literature to explore key factors influencing PCM implementation, highlighting the role of innovative leadership, interdisciplinary collaboration, and coordinated funding and regulatory strategies. Success in PCM relies on overcoming challenges such as integrating diverse medical disciplines, securing sustainable investment for shared infrastructures, and navigating complex regulatory landscapes. Effective leadership is crucial for fostering a culture of innovation and teamwork, essential for translating complex biological insights into personalized treatment strategies. The transition to PCM necessitates not only organizational adaptation but also the development of new professional roles and training programs, underscoring the need for a multidisciplinary approach and the importance of team science in overcoming the limitations of traditional medical paradigms. The conclusion underscores that PCM's success hinges on creating collaborative environments that support innovation, adaptability, and shared vision among all stakeholders involved in cancer care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.